Achieve Life (ACHV) grants Chief Commercial Officer 180,000 stock options at $4.36

Rhea-AI Filing Summary

Achieve Life Sciences, Inc. granted Chief Commercial Officer Jaime Xinos a stock option for 180,000 shares of common stock on January 28, 2026. The option has an exercise price of $4.36 per share.

One quarter of the award will vest on the first anniversary of January 28, 2026, with the remaining shares vesting in substantially equal monthly installments over the following 36 months, contingent on continued service. After the grant, Xinos beneficially owned 180,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xinos Jaime

(Last) (First) (Middle)

22722 29TH DR SE

SUITE 100

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	01/28/2026		A		180,000		(1)	01/28/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. The option will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	Sandra Thomson as attorney-in-fact for Jaime Xinos	01/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Achieve Life Sciences (ACHV) grant to Chief Commercial Officer Jaime Xinos?

Achieve Life Sciences granted Chief Commercial Officer Jaime Xinos a stock option covering 180,000 shares of common stock at a $4.36 exercise price. This award gives the right to buy shares in the future if the vesting and service conditions are met.

What is the vesting schedule for Jaime Xinos’s 180,000 ACHV stock options?

The option vests 25% on the first anniversary of January 28, 2026, with the remaining shares vesting in substantially equal monthly installments over 36 months. Vesting is conditioned on Xinos continuing to provide services on each vesting date.

At what price can Jaime Xinos exercise the new Achieve Life Sciences stock options?

The stock option granted to Jaime Xinos has an exercise price of $4.36 per share of Achieve Life Sciences common stock. This is the price Xinos must pay per share to exercise the option once the relevant portion has vested.

How many derivative securities does Jaime Xinos own after this ACHV option grant?

Following the reported transaction, Jaime Xinos beneficially owns 180,000 derivative securities in the form of stock options. These options represent rights to acquire Achieve Life Sciences common stock, subject to the specified vesting schedule and continued service conditions.

Is Jaime Xinos’s ownership in Achieve Life Sciences direct or indirect after this option grant?

The filing states that Jaime Xinos’s beneficial ownership of the 180,000 stock options is direct. There is no indication in the disclosure or footnotes that the options are held through a trust, LLC, or other indirect ownership structure.

What role does Jaime Xinos hold at Achieve Life Sciences (ACHV) in this Form 4 filing?

In this Form 4, Jaime Xinos is identified as an officer of Achieve Life Sciences, serving as Chief Commercial Officer. The reported stock option grant is compensation tied to this executive role and is subject to ongoing service with the company.